Study Examining the Safety and Toxicity of Stereotactic Body Radiotherapy (SBRT) Followed by PCX12 Immunotherapy Delivered by Intratumoral Injection for the Treatment of Patients With Locally Advanced Pancreatic Adenocarcinoma (LAPC)

Part of paid clinical trials in Rochester, New York.

Sponsor
Haoming (Carl) Qiu
Study ID
NCT06217666
Phase
PHASE1
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • PCX-12 — DRUG
    treatment combining radiation therapy with PCX12

Study Details

The purpose of this study is to determine whether a new treatment combining radiation therapy with PCX12 is safe and tolerable.

Key Dates

Start date
Dec 1, 2026
Status verified
Feb 2026
Primary completion
Dec 31, 2028
Completion
Dec 31, 2029

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: PCX-12
    PCX-12 is an experimental immunotherapy drug that is injected into the pancreatic cancer one time in attempt to stimulate the patient's immune system to fight the cancer.

Primary Outcome Measure

Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) [ Time Frame: 3 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of RochesterRochesterNew York14642
Haoming Qiu

Find similar trials in Rochester, NY

By condition
Pancreatic cancer
By specialty
OncologyGI oncology
By research site
University of Rochester· Rochester, NY

Related Studies